Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:BBIO NASDAQ:BPMC NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$39.050.0%$32.36$23.42▼$62.58$2.26B0.73653,319 shs319,729 shsBBIOBridgeBio Pharma$46.31+0.7%$38.37$21.72▼$46.84$8.78B1.152.52 million shs1.35 million shsBPMCBlueprint Medicines$129.31+0.6%$115.93$73.04▼$129.95$8.35B0.891.36 million shs4.95 million shsVRNAVerona Pharma PLC American Depositary Share$104.83+0.1%$82.60$16.91▼$104.99$8.50B0.241.56 million shs13.28 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+7.69%+10.52%+16.07%+54.37%-8.50%BBIOBridgeBio Pharma+6.46%+7.35%+17.81%+42.31%+78.91%BPMCBlueprint Medicines+0.12%+0.27%+0.45%+60.15%+11.54%VRNAVerona Pharma PLC American Depositary Share+20.62%+16.31%+23.78%+94.27%+514.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.0705 of 5 stars3.41.00.04.31.80.81.9BBIOBridgeBio Pharma4.6844 of 5 stars4.52.00.03.92.43.30.6BPMCBlueprint Medicines1.5263 of 5 stars2.14.00.00.02.20.80.6VRNAVerona Pharma PLC American Depositary Share1.7442 of 5 stars2.41.00.00.03.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6050.93% UpsideBBIOBridgeBio Pharma 3.00Buy$58.9327.69% UpsideBPMCBlueprint Medicines 2.24Hold$128.25-0.82% DownsideVRNAVerona Pharma PLC American Depositary Share 2.69Moderate Buy$107.452.39% UpsideCurrent Analyst Ratings BreakdownLatest AGIO, BBIO, BPMC, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$138.00 ➝ $107.007/10/2025VRNAVerona Pharma PLC American Depositary ShareBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/9/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$60.007/9/2025VRNAVerona Pharma PLC American Depositary ShareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$107.007/9/2025VRNAVerona Pharma PLC American Depositary ShareJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$140.00 ➝ $107.007/1/2025VRNAVerona Pharma PLC American Depositary ShareWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$170.006/30/2025BBIOBridgeBio PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $76.006/25/2025BBIOBridgeBio PharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $54.006/23/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$76.00 ➝ $160.006/20/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$107.00 ➝ $138.006/18/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.00 ➝ $116.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M61.61N/AN/A$27.02 per share1.44BBIOBridgeBio Pharma$127.42M68.78N/AN/A($7.71) per share-5.99BPMCBlueprint Medicines$508.82M16.41N/AN/A$4.70 per share27.51VRNAVerona Pharma PLC American Depositary Share$118.54M71.78N/AN/A$2.56 per share40.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.46N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)BBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A198.95N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,498.20N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest AGIO, BBIO, BPMC, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74N/AN/AN/AN/AN/A8/7/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/AN/AN/A8/7/2025Q2 2025BPMCBlueprint Medicines-$0.54N/AN/AN/AN/AN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93BBIOBridgeBio PharmaN/A4.574.54BPMCBlueprint Medicines1.012.802.75VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ABBIOBridgeBio Pharma99.85%BPMCBlueprint MedicinesN/AVRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%BBIOBridgeBio Pharma18.20%BPMCBlueprint Medicines4.21%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableVRNAVerona Pharma PLC American Depositary Share3081.08 million81.05 millionOptionableAGIO, BBIO, BPMC, and VRNA HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sees Large Volume Increase - Here's Why3 hours ago | marketbeat.comMerck to buy Verona Pharma for USD 10 billion4 hours ago | medicaldialogues.inMJefferies Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)4 hours ago | msn.comVerona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck4 hours ago | msn.comVerona Pharma PLC American Depositary Share's (VRNA) "Equal Weight" Rating Reaffirmed at Wells Fargo & CompanyJuly 10 at 8:52 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Neutral Rating from BTIG ResearchJuly 10 at 8:16 AM | marketbeat.comVerona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10BJuly 9 at 7:58 PM | msn.comVerona Pharma leaps on news of Merck & Co takeover bidJuly 9 at 7:58 PM | thepharmaletter.comTMerck confirms $10B buyout of Verona PharmaJuly 9 at 7:58 PM | msn.comMerck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug PortfolioJuly 9 at 7:58 PM | msn.comTop Mid Cap Stocks To Add to Your Watchlist - July 9thJuly 9 at 4:36 PM | marketbeat.comPromising Pharmaceutical Stocks To Watch Now - July 9thJuly 9 at 4:36 PM | marketbeat.comTop Medical Stocks Worth Watching - July 9thJuly 9 at 4:36 PM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given "Hold" Rating at Canaccord Genuity GroupJuly 9 at 4:26 PM | marketbeat.comVerona Pharma PLC American Depositary Share's (VRNA) Hold Rating Reaffirmed at Jefferies Financial GroupJuly 9 at 4:26 PM | marketbeat.comVRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to ShareholdersJuly 9 at 12:07 PM | businesswire.comMerck Buys Verona Pharma: A Good Deal, But M&A Spree Must ContinueJuly 9 at 11:59 AM | seekingalpha.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 52-Week High - Should You Buy?July 9 at 10:54 AM | marketbeat.comVerona Pharma Stock Jumps 20% on $10B Buyout Offer From MerckJuly 9 at 10:20 AM | zacks.comVerona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.July 9 at 7:14 AM | barrons.comMerck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next DecadeJuly 9 at 7:02 AM | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGIO, BBIO, BPMC, and VRNA Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$39.05 -0.02 (-0.05%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.BridgeBio Pharma NASDAQ:BBIO$46.31 +0.33 (+0.72%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Blueprint Medicines NASDAQ:BPMC$129.30 +0.76 (+0.59%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$104.83 +0.06 (+0.06%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Microsoft Keeps Showing Up in Congressional Portfolios Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
